ETNB
89bio, Inc.
7.66
USD
This page is just a preview of the data found in TrendSpider’s full version
89bio, Inc. stock is up 8.96% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 4 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 4 CALLs, 6 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 02 Oct 19:38 | 20 Oct, 2023 | 15.00 | 4201 | ||
| 03 Oct 13:53 | 17 Nov, 2023 | 20.00 | 2066 | ||
| 10 Oct 13:47 | 20 Oct, 2023 | 12.50 | 1059 | ||
| 10 Oct 13:47 | 20 Oct, 2023 | 12.50 | 1059 | ||
| 10 Oct 13:48 | 20 Oct, 2023 | 12.50 | 1059 | ||
| 10 Oct 13:54 | 21 Jun, 2024 | 7.50 | 0 | ||
| 10 Oct 13:59 | 21 Jun, 2024 | 7.50 | 0 | ||
| 10 Oct 17:35 | 17 Jan, 2025 | 10.00 | 160 | ||
| 10 Oct 17:41 | 19 Jan, 2024 | 10.00 | 420 | ||
| 12 Oct 18:53 | 19 Jan, 2024 | 10.00 | 260 |
89bio, Inc. focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21.
